Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
Corona Virus Infection
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Infection
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Severe Acute Respiratory Syndrome of Upper Respiratory Tract
Neurodegeneration
Neuroinflammatory Response

Interventions

DRUG: Drug: NA-831 - 0.10 mg/kg
DRUG: Placebo- 0.10 mg/kg
DRUG: Drug: NA-831 - 0.20 mg/kg
DRUG: Placebo- 0.20 mg/kg
DRUG: Drug: GS-5734 - 1.00 mg/kg
DRUG: Placebo- 1.00 mg/kg
DRUG: Drug: GS-5734 - 2.00 mg/kg
DRUG: Placebo- 2.00 mg/kg
COMBINATION_PRODUCT: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
COMBINATION_PRODUCT: Placebo 0.10 mg + 1.00 mg/kg
COMBINATION_PRODUCT: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)
COMBINATION_PRODUCT: Placebo 0.20 mg + 2.00 mg/kg

Sponsor

Biomed Industries, Inc.